Surge in spousal murders in India reflects deeper societal issues: NMHP Advisor
Hyderabad, June 11 (UNI) A surge in spousal murders in India reflects deeper societal issues where forced marriages and inability to express views about relationship choices can lead to violent outcomes, according to Dr Naresh Puohit, Advisor National Mental Health Programme (NMHP).
The recent tragic murder of Raja Raghuvanshi, a young businessman from Indore, allegedly killed by his wife, Sonam Raghuvanshi, during their honeymoon in Meghalaya is a heartbreaking reminder of the devastation caused by dishonesty in relationships.
Marriage is a sacred bond built on trust and mutual respect. When these values are absent, the consequences can be catastrophic, said Dr Naresh, noted Mental Health Expert.
Talking to UNI after addressing a Continuing Medical Education Programme (CME) on "Understanding Toxic Relationships" organised by the Hyderabad-based Institute of Mental Health here on Wednesday, Dr Purohit emphasised that instead of resorting to violence, individuals must have the courage to choose divorce or to walk away from marriages that conflict with their true feelings. Taking an innocent life is never the answer, it creates a cycle of pain and suffering for all involved.
Quoting his recent research paper titled "The Psychology Behind Spousal Killings", the Principal Investigator for the Association of Studies In Mental Care, pointed that one of the leading factors that makes spouses commit such heinous act is the desire to take over, control and dominate the relationship; and the failure to achieve that can lead to frustration, prompting them to kill their partner.
"The relationships where the partner has the intense ambition of jealousy and possessiveness can fuel anger and resentment, whereas little events can take up huge manifestations like killing or murdering the partner," he added
"The past experiences of an individual can lead to such killings. Where prior bad experiences may erode trust in the institution of marriage, leading to the killing of the partner," he said
He averred that several personality disorders, such as narcissistic personality disorder, where one is extremely egotistical or is very suspicious of the other partner, can predispose individuals to aggressive behaviors and a lack of empathy.
"According to the National Crime Records Bureau (NCRB) homicides resulting from love affairs and marital relationships are the third and fourth most prevalent motives for murder in India. Statistically, approximately one in ten murders in the nation is perpetrated by a lover, spouse, or partner."
"From 2010 to 2014, the proportion of murders linked to love affairs and relationships fluctuated between 7 percent and 8 percent. In contrast, from 2015 to 2022, this percentage increased to between 10 percent and 11 per cent, and the trend shows no signs of abating," the renowned physician added.
Experts pointed out that in most spousal crimes, the person isn't mentally ill; they just don't care how their emotions and actions affect others. It's much more than just poor mental well-being, it's complete moral erosion.
UNI KNR RN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine
Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
6 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine candidate
HYDERABAD: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licenced pharma giant GSK's Shigella vaccine candidate -- altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, which is a severe form of bacterial diarrhoea that largely affects children aged five years and below in low- and middle-income countries. While GSK has already conducted Phase-I and II trials in Europe and Africa, Bharat Biotech will be taking up further development with Phase-III clinical trials, regulatory advancement and large-scale manufacturing, Bharat Biotech said on Thursday. As part of the agreement, GSK will continue its support to the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalized modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. 'The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response,' the Hyderabad-based vaccine maker said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo 'Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it added. Bharat Biotech executive chairman Dr Krishna Ella said: 'With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment.' He pointed out that the addition of this vaccine candidate to its portfolio will strengthen Bharat Biotech's already significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. GSK already has an established relationship with BBIL, after it signed a product transfer agreement for the world's first malaria vaccine, RTS,S, to the Hyderabad-based company in 2021. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Hindustan Times
6 hours ago
- Hindustan Times
Neurotech and brain data: New frontier of privacy concerns
Consumer neurotechnology is no longer confined to sci-fi or academic labs. Thanks to AI advancements and shrinking chip sizes, devices that read brain activity, like EEG headsets, mood-tracking earbuds, and brain-controlled gaming accessories are entering the mainstream. Since 2011, over 130 startups have jumped into the consumer neurotech space. These tools, often embedded in wearables, promise productivity boosts, mental health insights, and immersive control over AR/VR environments. Tech giants like Apple and Snap are already exploring brain-computer interfaces (BCIs) for future headsets that could respond to mental states in real time. How Neurotech Works—And why It's risky EEG-based devices dominate this landscape, powering nearly 65% of consumer neurotech products. They track brainwave patterns linked to emotions, focus, and engagement levels. That may sound harmless until you realise this data could be mined to predict behaviours, preferences, or even political leanings. Imagine hyper-targeted ads based not on clicks, but on neural spikes. Or worse, cognitive surveillance, where employers or governments monitor attention levels, emotional stress, or signs of dissent. Cyberattacks targeting BCIs could introduce 'mental hacks', altering thought patterns or inducing confusion and distress. As one expert puts it, 'Brain data reveals thoughts before they're consciously expressed.' Regulatory gaps and urgent challenges The legal protections around all this? Alarmingly thin. While medical neurotech is regulated (MRIs or brain implants), consumer-grade EEG headsets fall into a grey zone. In the U.S., the FDA only monitors medical devices. State laws in places like California and Colorado require user consent for neural data use, but there's little enforcement. Internationally, concerns are mounting: China has tested neurotech in workplaces to track employee fatigue, while neuromarketing firms tap EEG feedback to fine-tune advertisements. 'Neural data could be weaponized for psychological warfare or blackmail.' Path forward So what now? We need clear federal laws that define how brain data can be collected, stored, and shared. Users should know exactly what's being tracked and who has access to it. Neural data must be encrypted, just like financial or medical records. Most importantly, the public must be made aware of what 'brain transparency' really means. Because the future of privacy may no longer be in your hands, but in your head. First Published Date: 12 Jun, 21:23 IST
